HNE-modified proteins in Down syndrome: Involvement in development of Alzheimer disease neuropathology
MetadataShow full item record
Down syndrome (DS), trisomy of chromosome 21, is the most common genetic form of intellectual disability. The neuropathology of DS involves multiple molecular mechanisms, similar to AD, including the deposition of beta-amyloid (Aβ) into senile plaques and tau hyperphosphorylationg in neurofibrillary tangles. Interestingly, many genes encoded by chromosome 21, in addition to being primarily linked to amyloid-beta peptide (Aβ) pathology, are responsible for increased oxidative stress (OS) conditions that also result as a consequence of reduced antioxidant system efficiency. However, redox homeostasis is disturbed by overproduction of Aβ, which accumulates into plaques across the lifespan in DS as well as in AD, thus generating a vicious cycle that amplifies OS-induced intracellular changes. The present review describes the current literature that demonstrates the accumulation of oxidative damage in DS with a focus on the lipid peroxidation by-product, 4-hydroxy-2-nonenal (HNE). HNE reacts with proteins and can irreversibly impair their functions. We suggest that among different post-translational modifications, HNE-adducts on proteins accumulate in DS brain and play a crucial role in causing the impairment of glucose metabolism, neuronal trafficking, protein quality control and antioxidant response. We hypothesize that dysfunction of these specific pathways contribute to accelerated neurodegeneration associated with AD neuropathology. © 2017 Elsevier Inc.
Showing items related by title, author, creator and subject.
ReviewBarone E.; Arena A.; Head E.; Butterfield D.A.; Perluigi M. (Elsevier Inc., 2018)
Autophagic dysfunction in Alzheimer’s disease: Cellular and molecular mechanistic approaches to halt Alzheimer’s pathogenesis (2020) Uddin M.S.; Mamun A.A.; Labu Z.K.; Hidalgo-Lanussa O.; Barreto G.E.; Ashraf G.M. (Wiley-Liss Inc., 2019)
APOE and Alzheimer’s Disease: Evidence Mounts that Targeting APOE4 may Combat Alzheimer’s Pathogenesis (2020) Uddin M.S.; Kabir M.T.; Al Mamun A.; Abdel-Daim M.M.; Barreto G.E.; Ashraf G.M. (Humana Press Inc., 2019)